Exarafenib

N/A

Report date: 2022/10/25 14:55:45
NME

Base Information

Drug NameExarafenib
Drug Alias NameKIN-2787KIN-002787
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase B-raf inhibitorsC-Raf kinase inhibitors
TargetsSerine/threonine-protein kinase B-rafC-Raf kinase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanNetherlands +[11] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesKinnate Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesPierre Fabre Médicament SASerán BioScience IncKinnjiu Biopharma Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A